The importance of FcRn in neuro-immunotherapies: From IgG catabolism, gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors

by Marinos C. Dalakas, Peter J. Spaeth
Published 2021-02-01

On the dark side of therapies with immunoglobulin concentrates. The adverse events

by Peter J. Spaeth, Guido eGranata, Fabiola eLa Marra, Taco W. Kuijpers, Isabella eQuinti
Published 2015-02-01

Is dosing of therapeutic immunoglobulins optimal? – A review of a 3-decade long debate in Europe.

by Jacqueline eKerr, Isabella eQuinti, Martha eEibl, Helen eChapel, Peter J Spaeth, WA Carrock eSewell, Abdulgabar eSalama, Ivo N van Schaik, Taco W Kuijpers, Hans-Hartmut ePeter
Published 2014-12-01